Volume 3, Issue 1 (6-2021)
pbp 2021, 3(1): 34-36 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Karimi M, Gholami-Ahangaran M. A Brief Report on Current Evidence of Traditional Chinese Medicine in the Treatment of Patients Infected with SARS-CoV-2. pbp 2021; 3 (1) :34-36
URL: http://pbp.medilam.ac.ir/article-1-56-en.html
URL: http://pbp.medilam.ac.ir/article-1-56-en.html
1- Department of Clinical Sciences, Faculty of Veterinary Medicine, Shahrekord Branch, Islamic Azad University, Shahrekord, Iran , ma.karimivet58@gmail.com
2- Department of Clinical Sciences, Faculty of Veterinary Medicine, Shahrekord Branch, Islamic Azad University, Shahrekord, Iran
2- Department of Clinical Sciences, Faculty of Veterinary Medicine, Shahrekord Branch, Islamic Azad University, Shahrekord, Iran
Abstract: (1725 Views)
Coronavirus Disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus type 2 (SARS-CoV-2) which has become a major threat to public health worldwide. During 2003 and 2012, the Severe Acute Respiratory Coronavirus (SARS-CoV) and Middle East Respiratory Syndrome Coronavirus (MERS-CoV) had human epidemics. Because of similar characteristics among SARS-CoV-2 and other coronaviruses, they can be used by physicians to treat similar severe patients. During the past decade, traditional medicine has been widely used for the epidemic outbreaks such as SARS, H1N1 influenza, and MERS. In this review, the researchers summarized the recent findings and evidence of herbal formula of TCM in the treatment of COVID-19.
Type of Study: Review/Systemtic review |
Subject:
Herbal Drugs
Received: 2020/09/23 | Accepted: 2021/04/11 | Published: 2021/07/6
Received: 2020/09/23 | Accepted: 2021/04/11 | Published: 2021/07/6
References
1. Rodriguez-Morales AJ, Balbin-Ramon GJ, Rabaan AA, Sah R, Dhama K, Paniz-Mondolfi A, et al. Genomic Epidemiology and its importance in the study of the COVID-19 pandemic. Infez Med 2020; 28 (2): 139-42.
2. Lombardy Section Italian Society I, Tropical D. Vademecum for the treatment of people with COVID-19. Edition 2.0, 13 March 2020. Infez Med 2020; 28 (2): 143-52.
3. Rabaan AA, Al-Ahmed SH, Haque S, Sah R, Tiwari R, Malik YS, et al. SARS-CoV-2, SARS-CoV, and MERS-COV: A comparative overview. Infez Med 2020; 28 (2): 174-84.
4. Yang Y, Islam MS, Wang J, Li Y, Chen X. Traditional Chinese Medicine in the Treatment of Patients Infected with 2019-New Coronavirus (SARS-CoV-2): A Review and Perspective. International journal of biological sciences 2020; 16 (10): 1708-17.
5. Zhang H, Chen Q, Zhou W, Gao S, Lin H, Ye S, et al. Chinese medicine injection shuanghuanglian for treatment of acute upper respiratory tract infection: a systematic review of randomized controlled trials. Evid Based Complement Alternat Med 2013; 2013: 987326.
6. Ho TY, Wu SL, Chen JC, Li CC, Hsiang CY. Emodin blocks the SARS coronavirus spike protein and angiotensin-converting enzyme 2 interaction. Antiviral Res 2007; 74 (2): 92-101.
7. Deng YF, Aluko RE, Jin Q, Zhang Y, Yuan LJ. Inhibitory activities of baicalin against renin and angiotensin-converting enzyme. Pharm Biol 2012; 50 (4): 401-6.
8. Chen Z, Nakamura T. Statistical evidence for the usefulness of Chinese medicine in the treatment of SARS. Phytother Res 2004; 18 (7): 592-4.
9. Takahashi S, Yoshiya T, Yoshizawa-Kumagaye K, Sugiyama T. Nicotianamine is a novel angiotensin-converting enzyme 2 inhibitor in soybean. Biomed Res 2015; 36 (3): 219-24.
10. Wang W, Ma X, Han J, Zhou M, Ren H, Pan Q, et al. Neuroprotective Effect of Scutellarin on Ischemic Cerebral Injury by Down-Regulating the Expression of Angiotensin-Converting Enzyme and AT1 Receptor. PLoS One 2016; 11 (1): e0146197.
11. Luo H, Tang QL, Shang YX, Liang SB, Yang M, Robinson N, et al. Can Chinese Medicine Be Used for Prevention of Corona Virus Disease 2019 (COVID-19)? A Review of Historical Classics, Research Evidence and Current Prevention Programs. Chin J Integr Med 2020; 26 (4): 243-50.
12. Zhang D, Zhang B, Lv JT, Sa RN, Zhang XM, Lin ZJ. The clinical benefits of Chinese patent medicines against COVID-19 based on current evidence. Pharmacol Res 2020: 104882.
13. National Health Commission of the People's Republic of China. Notice on the issunance of guidelines of diagnosis and treatment for 2019-nCoV infected pneumonia (version 6) 6 ed; http://www.nhc.gov.cn/yzygj/s7653p/202002/8334a8326dd94d329df351d7da8aefc2.shtml?from=timeline. 2020.
14. Chang X, Zhang S, Jiang Y, Chen C, Chen J, Liu B, et al. Mechanism of Reduning Injection on anti-acute lung injury in rats based on cytokine storm. Chin Tradit Herb Drugs 2015; 46 (2): 236-39.
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |